La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
TG Therapeutics Gestione
Gestione criteri di controllo 3/4
TG Therapeutics' Il CEO è Mike Weiss, nominato in Dec2011, e ha un mandato di 12.67 anni. la retribuzione annua totale è $ 15.84M, composta da 5.5% di stipendio e 94.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.72% delle azioni della società, per un valore di $ 206.58M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 12.7 anni e 10.7 anni.
Informazioni chiave
Mike Weiss
Amministratore delegato
US$15.8m
Compenso totale
| Percentuale dello stipendio del CEO | 5.5% |
| Mandato del CEO | 12.7yrs |
| Proprietà del CEO | 5.7% |
| Durata media del management | 12.7yrs |
| Durata media del Consiglio di amministrazione | 10.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09
TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$96m |
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | US$16m | US$875k | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
Compensazione vs Mercato: La retribuzione totale di Mike ($USD 15.84M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).
Compensazione vs guadagni: La retribuzione di Mike è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Mike Weiss (58 yo)
12.7yrs
Mandato
US$15,837,559
Compensazione
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.7yrs | US$15.84m | 5.72% $ 206.6m | |
| CFO, Corporate Secretary & Treasurer | 12.7yrs | US$1.87m | 0.48% $ 17.2m | |
| Senior Vice President of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Commercialization Officer | 6.2yrs | Nessun dato | Nessun dato |
12.7yrs
Durata media
Gestione esperta: Il team dirigenziale di TGTX è esperto e expertise (durata media dell'incarico 12.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 12.7yrs | US$15.84m | 5.72% $ 206.6m | |
| Lead Independent Director | 12.3yrs | US$304.70k | 0.17% $ 6.0m | |
| Independent Director | 9.7yrs | US$264.70k | 0.18% $ 6.7m | |
| Independent Director | 11.8yrs | US$262.20k | 0.17% $ 6.1m | |
| Independent Director | 4.3yrs | US$259.70k | 0.073% $ 2.6m | |
| Independent Director | 9.2yrs | US$262.20k | 0.17% $ 6.1m |
10.7yrs
Durata media
58.5yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di TGTX è composto da personale esperto e esperto (durata media dell'incarico 10.7 anni).